The metabolic syndrome. Selected aspects - A review;Metabolisches Syndrom

Praxis

Volumn 92, Issue 15, 2003, Pages 681-688

  Suter, P M ^a  

^a UNIVERSITÄTSSPITAL ZÜRICH   (Switzerland)

Author keywords

Cardiovascular risk; Lipotoxicity; Metabolic syndrome; Obesity; Overweight

Indexed keywords

FATTY ACID; GLUCOSE; LIPID; TRIACYLGLYCEROL;

BLOOD; CARDIOVASCULAR DISEASE; COMPARATIVE STUDY; DIET; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERINSULINISM; HYPERLIPIDEMIA; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; REVIEW; RISK FACTOR; SEX DIFFERENCE;

BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIET; FATTY ACIDS, NONESTERIFIED; FEMALE; GLUCOSE; HUMANS; HYPERINSULINISM; HYPERLIPIDEMIAS; INSULIN RESISTANCE; LIPIDS; MALE; METABOLIC SYNDROME X; OBESITY; RISK FACTORS; SEX FACTORS; TRIGLYCERIDES;

EID: 84860390708     PISSN: 16618157     EISSN: 16618165     Source Type: Journal    
DOI: 10.1024/0369-8394.92.15.681     Document Type: Review

References (38)

1. McLaughlin T, Reaven G. Insulin resistance and hypertension. Patients in double jeopardy for cardiovascular disease. Geriatrics 2000; 55: 28-32.
2. LeRoith D. Beta-cell dysfunction and insulin resistance in type 2 diabetes: role of metabolic and genetic abnormalities. Am J Med 2002; 113 (Suppl 6A): 3S-11S. (Pubitemid 35335936)
3. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607. (Pubitemid 19004941)
4. Reaven G. Metabolic syndrome: pathophysiology and implications for management of cardiovascular disease. Circulation 2002; 106: 286-288. (Pubitemid 34778947)
5. Groop L, Orho-Melander M. The dysmetabolic syndrome. J Intern Med 2001; 250: 105-120. (Pubitemid 32868690)
6. Lebovitz HE. Insulin resistance: definition and consequences. Exp Clin Endocrinol Diabetes 2001; 109: S135-S148 (Suppl. 2).
7. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414: 782-787. (Pubitemid 34000780)
8. Bosello O, Zamboni M. Visceral obesity and metabolic syndrome. Obes Rev 2000; 2000: 47-56.
9. Kraegen EW, Cooney GJ, Ye JM, Thompson AL, Furler SM. The role of lipids in the pathogenesis of muscle insulin resistance and beta cell failure in type II diabetes and obesity. Exp Clin Endocrinol Diabetes 2001; 109 (Suppl 2): S189-S201 (Pubitemid 32577582)
10. Busetto L. Visceral obesity and the metabolic syndrome: effects of weight loss. Nutr Metab Cardiovasc Dis 2001; 11: 195-204. (Pubitemid 33686565)
11. Wallace TM, Matthews DR. The assessment of insulin resistance in man. Diabet Med 2002; 19: 527-534. (Pubitemid 35300672)
12. Adult-Treatment-Panel-III. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-3421.
13. Friedlander Y, Kidron M, Caslake M, Lamb T, McConnell M, Bar-On H. Low density lipoprotein particle size and risk factors for insulin resistance syndrome. Atherosclerosis 2000; 148: 141-149.
14. Hollenberg NK. Genetic versus environmental etiology of the metabolic syndrome among male and female twins. Curr Hypertens Rep 2002; 4: 178.
15. St-Pierre J, Lemieux I, Miller-Felix I, et al. Visceral obesity and hyperinsulinemia modulate the impact of the microsomal triglyceride transfer protein -493G/T polymorphism on plasma lipoprotein levels in men. Atherosclerosis 2002;: 317-324.
16. Alberti K, Zimmet P, Consultation W. Definition, diagnosis, and classification of diabetes mellitus and it complications. Part 1: diagnosis and classification of diabetes mellitus, provisional report of a WHO consultation. Diabetic Med 1998; 15: 539-553.
17. Suter PM. Checkliste Ernährung. Stuttgart-New York: Georg Thieme Verlag, 2002.
18. Kylin E. Studien über das Hypertonie-Hyperglykämie- Hyperurikämie Syndrom. Zentralblatt für Innere Medizin 1923; 44: 105-127.
19. Austin AM. Plasma triglyceride as a risk factor for coronary heart disease. Am J Epidemiol 1989; 129: 249-259.
20. Austin MA. Epidemiology of hypertriglyceridemia and cardiovacular disease. Am J Cardiol 1999; 13: 13F-16F.
21. Taghibiglou C, Carpentier A, Van-Inderstine SC, et al. Mechanisms of Hepatic Very Low Density Lipoprotein Overproduction in Insulin Resistance. J Biol Chem 2000; 275: 8416-8425.
22. de-Knegt RJ. Non-alcoholic steatohepatitis: clinical significance and pathogenesis. Scand J Gastroenterol Suppl 2001; 234 (Supplement): 88-92.
23. Arner P. Insulin resistance in type 2 diabetes: role of fatty acids. Diabetes Metab Res Rev 2002; 118 (Suppl 2): S5-S9. (Pubitemid 34467308)
24. Maedler K, Sergeev P, Ris F, et al. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest 2002; 110: 851-860.
25. Petersen KF, Shulman GI. Pathogenesis of skeletal muscle insulin resistance in type 2 diabetes mellitus. Am J Cardiol 2002; 90: 11G-18G. (Pubitemid 35266676)
26. Lee JS, Bruce CR, Tunstall RJ, Cameron-Smith D, Hugel H, Hawley JA. Interaction of exercise and diet on GLUT-4 protein and gene expression in-Type I and Type II rat skeletal muscle. Acta Physiol Scand 2002; 175: 37-44. (Pubitemid 34534003)
27. Kelley DE. Skeletal muscle triglycerides: an aspect of regional adiposity and insulin resistance. Ann N Y Acad Sci 2002; 967: 135-145. (Pubitemid 34721901)
28. Smith U. Impaired ('diabetic') insulin signaling and action occur in fat cells long before glucose intolerance--is insulin resistance initiated in the adipose tissue? Int J Obes Relat Metab Disord 2002; 26: 897-904. (Pubitemid 34756170)
29. Egger S, Wieland R, Ludin M, Brändli O, Vetter W, Suter P. Übergewicht und Adipositas im Kanton Zürich: Eine LuftiBus Studie. PRAXIS (Schweizerische Rundschau für Medizin) 2001; 90: 531-538. (Pubitemid 33707165)
30. Zurlo F, Lillioja S, Esposito-Del Puente A, et al. Low ratio of fat to carbohydrate oxidation as predictor of weight gain: study of 24-h RQ. Am J Physiol 1990; 259 (5 Pt 1): E650-E657. (Pubitemid 20385711)
31. Lapidus L, Bengtsson C. Regional obesity as a health hazard in women - a prospective study. Acta Med Scand 1988; (723 (Suppl.): 53-59.
32. Lapidus L, Bengtsson D, Larsson BO, Pennert K, Rybo E, Sjoestroem L. Distribution of adipose tissue and risk of cardiovascular disease and death: a 12 year follow up of participants in the population study of women in Gothenburg, Sweden. Br Med J 1984; 289: 1257-1261. (Pubitemid 15217605)
33. Wajchenberg BL. Subcutaneous and Visceral Adipose Tissue: Their Relation to the Metabolic Syndrome. Endocrine Reviews 2000; 21: 697-738. (Pubitemid 32113289)
34. Frayn KN. Adipose tissue as a buffer for daily lipid flux. Diabetologica 2002; 45: 1201-1210.
35. Lupattelli G, Pasqualini L, Siepi D, et al. Increased postprandial lipemia in patients with normolipemic peripheral arterial disease. Am Heart J 2002; 143: 733-738. (Pubitemid 34454709)
36. Tiret L, Gerdes C, Murphy MJ, et al. Postprandial response to a fat tolerance test in young adults with a paternal history of premature coronary heart disease - the EARS II study (European Atherosclerosis Research Study). Eur J Clin Invest 2000; 30: 578-585. (Pubitemid 30453657)
37. Suter PM, Gerritsen Zehnder M, Häsler E, Gürtler M, Vetter W, Hänseler E. Effect of alcohol on postprandial lipemia with and without preprandial exercise. J Am Coll Nutr 2001; 20: 58-64. (Pubitemid 32244966)
38. Laaksonen DE, Lakka HM, Salonen JT, Niskanen LK, Rauramaa R, Lakka TA. Low levels of leisure-time physical activity and cardiorespiratory fitness predict development of the metabolic syndrome. Diabetes care 2002; 25: 1612-1618. (Pubitemid 41071120)